drugset / Trial / NCT02741323
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Maraviroc (MVC) is a type of HIV medicine called a CCR5 inhibitor. This study will evaluate the safety and tolerability of MVC in HIV-infected adults receiving a kidney transplant.
Timeline
- Start
- 2017-01-01
- Primary completion
- 2022-05-10
- Completion
- 2022-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 150 mg | — |
| Subject | Maraviroc | Other / unclassified | 300 mg | — |
| Subject | Maraviroc | Other / unclassified | 600 mg | — |